Leukoencephalopathy with neuroaxonal spheroids

Last updated
Leukoencephalopathy with neuroaxonal spheroids
Specialty Neurology

Leukoencephalopathy with neuroaxonal spheroids (LENAS), also known as adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), hereditary diffuse leukoencephalopathy with spheroids (HDLS) and pigmentary orthochromatic leukodystrophy (POLD) [1] is an extremely rare kind of leukoencephalopathy and is classified as a neurodegenerative disease. LENAS is a cause of severe and subacute dementia that results from damage to certain areas of the brain. This damage is to a type of brain tissue called white matter and axon damage due to swellings which are termed spheroids. [2]

Contents

The rarity and unknown prevalence of this disease may be due to most symptoms being similar to other common disorders, leading to misdiagnosis. [3] LENAS normally has an adult onset (but also can be present in childhood), which can present on MRIs that mimics progressive multiple sclerosis and is thus misdiagnosed for this instead. [4]

The genetic etiology of LENAS is known to follow an autosomal dominant pattern through a mutation in the CSF1R gene.

Signs and Symptoms

The signs and symptoms that are present vary with each individual as some may have all symptoms while some may only have some listed below. However, the progression of this disease is different with each individual which reflects how the symptoms change over time. Further, the damage that we see to the myelin and axons is thought to contribute to many of the neurological signs and symptoms that are shown in this condition. [2] The most frequent symptoms are categorized into psychiatric, psychotic and neurologic. [5]

Predominant Symptoms Based on Category [5]
CategorySymptoms
Psychiatric Depression, Anxiety, Alcohol use disorder, Irritability, and Aggressiveness
Psychotic Confusion, Delusions, and Hallucinations
Neurologic Dementia, Seizures, Impaired Balance, Retropulsion, Gait Apraxia, Spasticity, Ataxia, and Urinary Incontinence

General Symptoms

While these vary among individuals as mentioned, over time, almost all patients with this condition will be unable to walk, speak and care for themselves. [2]

Causes

Diagram of normal neuron showing myelin covering axon without damage (myelin sheath is in light blue). Neuron with oligodendrocyte and myelin sheath-2.svg
Diagram of normal neuron showing myelin covering axon without damage (myelin sheath is in light blue).

Leukoencephalopathy with neuroaxonal spheroids (LENAS) is believed to occur when presence of white matter degeneration and axonal spheroids are seen with a brain biopsy or an MRI. [6] [3]

White matter consists of nerve fibers (axons) covered by a substance called myelin that insulates and protects them. [3] The axons extend from nerve cells (neurons) and transmit nerve impulses throughout the body. [3]

The result of spheroids in the brain leads to this significant decline of functioning that progressively worsens the brain function and leads to varied symptoms. However, why this occurs is still not entirely understood, thus more research is continuously being done to this day.

There have been identifiable genetic differences that are better understood. This disease is inherited while following an autosomal dominant pattern.

Genetic Etiology

There are identifiable genetic causes that are better understood with this disease. LENAS is caused by a mutation in a gene, specifically the CSF1R gene. This mutation changes protein receptors on the gene which normally plays a role in important cell signaling pathways; however, this altercation inhibits the regular function. [2]

Normal Function of CSF1R Gene

The colony stimulating factor 1 receptor (CSFR1) gene regularly functions by giving instructions for making a protein termed the colony stimulating factor 1 receptor (CSF-1 receptor). [7] Proteins in general attach (bind) to their specific receptor which "turns on" (activates) to stimulate a cascade of cellular signaling pathways crucial for cell function to occur. These events occur with the specific CSF-1 protein. As it binds and is activated, it allows for important cellular processes to occur which include cell growth, division, and maturation of cells to in turn take on specific functions. [7]

Visual representation of what occurs due to a missense mutation like in a mutated CSF1R gene seen in LENAS Missense Mutation Example.jpg
Visual representation of what occurs due to a missense mutation like in a mutated CSF1R gene seen in LENAS

Glial cells, located in the brain, are responsible for protection and maintenance of neurons. In a healthy brain, the membrane of glial cells are abundant with the CSF-1 receptor gene and is also thought to be an important player in the proliferation and differentiation of these cells. [7]

Leukoencephalopathy with neuroaxonal spheroids
Autosomal dominant - en.svg
This condition is inherited in an autosomal dominant manner
Specialty Neurology

Mutated CSF1R Gene

There are several types of mutations that occur in genes. The majority of CSF1R genetic mutations in LENAS occur due to a type of mutation which is called a missense mutation. [3] Missense mutations occur when there is a change in a single amino acid of a protein. This single change can result in problems with functions of the protein, like the CSF-1 receptor. The kinase domain, which is the region of CSF-1 receptor where the mutation occurs, is altered and thus the normal function that activates other proteins is compromised and cannot stimulate cell signaling pathways properly. [3]

Although this is the primary type of mutation in LENAS, other types may occur as well but it is not as well understood for this disease. [3]

This genetic mutation is related to LENAS and said to be the main cause but how these lead to damage in the white matter and associated symptoms (cognitive and movement impairment symptoms) is still not fully clear. [3] [7]

Inheritance

LENAS is inherited in an autosomal dominant pattern. This means that one copy of the mutated gene in each cell is sufficient to cause the disorder. [2]

If one parent who is unaffected and one parent who is affected with LENAS give birth to four children, at least two of the four will become affected and have the disorder because the affected parent would pass on the one copy of the gene. In most cases, an affected person does inherit the mutation from one affected parent but not all cases.

There have been very few reports of cases that result from new mutations have been seen as well as cases in which there has been no history of LENAS. [2] These few reports are not as concrete or well understood yet and further studies should be conducted.

Pathophysiology

Neuropathology

View of the lobes and major external structures of the human brain Lobes of the brain.jpg
View of the lobes and major external structures of the human brain

LENAS is seen with damage to the white matter and axons within the brain. The external human LENAS brain shows findings in several major structures. There is mild atrophy of the frontoparietal regions of the brain and a mild reduction of the thalamus and rostral (front) part of the caudate nucleus (which is located in an area of the brain called the basal ganglia). [5] Abnormalities in the frontal, frontoparietal, and temporal lobes are most severe and predominant with LENAS and asymmetry of the cerebral hemispheres has sometimes been found. [5] LENAS also may show moderately enlarged lateral ventricles and atrophy in corticospinal tracts as well as in the pons. [5]

The area where it is seen to be the most pronounced abnormalities appear in the white matter below the pre- and postcentral gyri that extend through the posterior limb of the internal capsule into pyramidal tracts of the brain stem. [5]

Location of important brain structures associated with LENAS. Note the thalamus and corpus callosum. 1511 The Limbic Lobe.jpg
Location of important brain structures associated with LENAS. Note the thalamus and corpus callosum.

Specific Immunostains are used as the easiest identification of neuroaxonal spheroids in LENAS which appear as round to oval shaped swellings and are seen in affected white matter. [5] If there appears to be a large amount of loss in myelin sheaths on axons and these spheroids, LENAS progressed to become widespread. [5]

Electron Microscopy has also been used to identify spheroids. In LENAS, evidence of the spheroids may show neurofilaments that are scattered amount electron-dense material and mitochondria. [5]

Subcortical U-fibers in the brain appear to be relatively spared, meaning they seem to not be involved in most cases but this does not mean they are not always/eventually involved. [5] [8] U-fibers represent connections which are between adjacent areas of the brain located within the cortex or deep in the white matter that are one of the last parts of the brain to be myelinated. [8] In LENAS, it has been found that because these U-fibers are last to myelinate normally, they are also last to be affected as the disease progresses.

Biochemistry

The primary biochemical defect in LENAS disrupts normal states and may involve oxidative stress. Ceroids, which are essentially products of unsaturated fatty acids that build up, are found in macrophages and other glia is thought to be an end-product of oxidative damage, indicative of membrane damage from abnormal accumulation. [9]

The high levels of Iron is also present in LENAS which can be associated to cause an increased level of toxic free radicals and causing oxidative damage to the body, causing failure in our cellular energy systems. [10]

Disease Mechanism

The mechanism of LENAS still seems to remain unclear and it varies as more research on this is being done. Some mechanisms that can be of clinical importance of why individuals show certain symptoms and which area of the brain has been shown to be consistent. [10]

Normally, the frontal lobe in our brain are important for our higher level executive functions. Predominance of white matter damage in this lobe has been found to be consistent with both the psychiatric and behavioral signs and symptoms pertaining to LENAS. [10] The underlying symptoms seen of frontotemporal dementia seen commonly in LENAS is associated with the temporal lobe damage. [10] There is a large disconnect in the brain between the lobes that reflect the neuropsychiatric symptoms that are common with the disease. [10]

Ataxia, which is related to our daily voluntary movements of muscles, are often present even in patients without cerebellar involvement which could reflect either minimal damage to the cerebellum or diffuse cerebral white matter lesions. [10]

Diagnosis

The diagnosis of LENAS is usually based on medical and family history, genetic testing, extensive imaging and other supplemental testing. As this disease is extremely rare, diagnosis is still very complex as many of these diagnostic criteria for LENAS can be mistaken for similar neurodegenerative disorders. The differential diagnosis of leukoencephalopathy in general is very extensive and specialized investigations are required to make an accurate diagnosis. [11]

Diagnostic Criteria

Note: These criteria were established by a group consisting of board-certified neurologists from the Mayo Clinic, Niigata University, Shinshu University School of Medicine, Kyoto Prefectural University of Medicine, and Tokushima University Graduate School.

Brain CT of brain showing white matter lesions (indicated by the red arrows) White Matter Lesions (48601156232).jpg
Brain CT of brain showing white matter lesions (indicated by the red arrows)

Core Features

  1. Age at onset ≤ 60 years old [11]
  2. More than 2 findings of the following clinical signs and symptoms: [11]
    1. Cognitive Impairment or Psychiatric Symptoms [11]
    2. Pyramidal Signs [11]
    3. Parkinsonism [11]
    4. Epilepsy [11]
  3. Autosomal Dominant inheritance or sporadic occurrence [11]
  4. Brain CT/MRI findings:
    1. Bilateral Cerebral white matter lesions [11]
    2. Thinning of the Corpus Callosum [11]
  5. Other causes of Leukoencephalopathy including vascular dementia, multiple sclerosis, or leukodystrophy can be excluded. [11]

Exclusionary Findings

  1. Age at onset ≤ 10 years [11]
  2. Stroke-like episodes more than twice except for epilepsy [11]
  3. Prominent peripheral neuropathy [11]

Supportive Findings

  1. Frontal lobe dysfunction shown by clinical features or cognitive battery test [11]
  2. Rapidly progressive course. Become bedridden within 5 years after onset [11]
  3. Spotty small calcifications in the white matter shown by brain CT [11]
  4. Neuropathologic findings compatible to LENAS [11]
Diagnosis By Criteria
DefiniteProbablePossible
Fulfills core features 2,3 and 4A and confirmation of CSF1R mutation [11] Fulfills core features 1-5, but genetic testing has not been performed [11] Fulfills core features 2a, 3, and 4a, but genetic testing has not been performed [11]

Genetic Testing

Single-Gene testing is first performed for sequence analysis of the CSF1R gene. [12]

A multi-gene panel that includes CSF1R gene and other genes of interest may be considered for differential diagnoses. [12]

If necessary, more comprehensive genomic testing (not always available though) can be performed. [12]

Testing Resources

ALSP Aware is a testing opportunity provided at no-cost for individuals with a family history of Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP). It is also available to physicians to test individuals that they suspect may have ALSP.

Eligibility Requirements

Further Evaluations

Prevention

There currently is not any suggestive findings of preventative measures that should be taken for LENAS before diagnosis. However, prevention of secondary complications can be taken once diagnosis is confirmed.

Prevention of Secondary Complications

Social problems such as unemployment, divorce, financial troubles, and alcoholism as well as suicidal tendencies are often associated as this disease worsens over time. Some of these social consequences may be avoided if family members are informed early about the nature of this disorder as well as if it is diagnosed early enough. [12]

As depression is a major symptom associated, suicidal tendencies may occur. Antidepressant medications can be prescribed for this depression for the attempt to help with depression but they have not shown long-term benefit to date. [12]

Agents and Circumstances to Avoid

The following should be avoided not to prevent the disease, but rather to prevent this disease from progressing faster and causing symptoms to worsen:

Treatment

No specific therapy for LENAS is currently known or proven to cure this disease, but management of it should be immediately initiated following diagnosis. While more research should be taken, some suggest that hematopoietic stem cell transplantation may show a therapeutic role for this disease. [12]

Management

Management is important in support of this disease and includes attention to general care and nutrition requirements and other possible drug therapies that may help or slow the progression of the disease. [12]

L-dopa or other dopaminergic therapies have not yet been beneficial in individuals with this disease but was noted that it may be worth trying as it does not show negative effects. [12]

Antipsychotics are in general not recommended due to extrapyramidal side effects. However, they may be used in aggressive individuals. [12]

Anti-seizure medications should be initiated in individuals who are having seizure activity along with having this disease as it is reported to be beneficial. [12]

Surveillance

Periodic clinical evaluation and surveillance to monitor the progression of the disease is appropriate to determine if changes need to be made:

Prognosis

Concept of a Lumbar Puncture being performed Blausen 0617 LumbarPuncture.png
Concept of a Lumbar Puncture being performed

Because of how rare this genetic condition is an exact prognosis is still not known and varies. Some data has suggested that the median age of onset is 45 years old, but patients with onset as young as 18 years old has also been described. [6] Further, it is believed that the median life expectancy is 6 years but is also extremely variable as it has also been reported that some patients survived up to 29 years after the onset of symptoms. [6]

While gaining a definitive prognosis for this disease studies suggest a few different techniques that may or may not benefit in getting a better prognosis for the individual patient:

Epidemiology

Epidemiological studies for rare diseases are difficult to have exact and known values that are still difficult to find. However, most studies show the mean age of onset was 43 years old (range 18–78 years old), with a mean death at 53 years (range 23–84 years) and the mean disease duration was found to be 6.8 years (range 1–29 years). [15]

History

LENAS was first reported in multiple members of a large Swedish pedigree in 1984. In this family, 17 out of 71 subjects from 4 generations were affected with this disease. [5] It was found that the age onset of this family varied from 8 to 60 years of age. [5] The age of death in this family was 39 to 89 years with a time between onset and death varied from 3 months to over 30 years. [5] Some patients in this family rapidly developed severe dementia and died a few months after this onset whereas others had a more prolonged progression of the disease. [5] This family was also to have reported sporadic patients as well. [5]

Prevalence

To date, the prevalence of this disease is unclear. Literature has few publications to date of this due to the rarity of the disease. However, a study done in 2011 found information dating back to 1970 that identified 51 individual cases fulfilling criteria to be identified. [16] Today, there could be more confirmed cases but these data have not increased significantly.

Research

The need for future research in this disease is necessary for varied reasons. First, this disease is still so rare and it is to this date very difficult to diagnose. Further, the signs and symptoms of this disease are often confused with other diseases that are more well known and misdiagnosis often occurs. This disease can commonly be mistaken for Multiple Sclerosis (MS) or another form of a more common leukoencephalopathy or neurodegenerative diseases as well. However, some current research has been done primarily on case studies in which scientists are attempting to find new mutations or new ways to diagnose. There are a few studies however that pose to lean in the direction of therapeutical's using hematopoietic stem cell transplantation therapy.

Hematopoietic stem cells can develop into a vast variety of different cells in our body themselves (self-differentiation). Stem cell differentiation.svg
Hematopoietic stem cells can develop into a vast variety of different cells in our body themselves (self-differentiation).

Hematopoietic Stem Cell Therapy

Bone marrow is the soft spongy area in some larger bones of the body that produces many cells which make up red blood cells, white blood cells and platelets. [17] These cells are developed from a type of cell found in bone marrow, termed hematopoietic stem cells. [17] The body is able to direct these stem cells to develop in the blood at any given moment and this is a rapid process. [17] Most of the stem cells remain in the marrow until they are mature which then they are released for specific functions in the body such as carrying oxygen, providing infection protection, and helping blood clotting. [17] Stem cells found in circulating blood are able to be extracted for stem cell therapy use and research. [17]

A study done using hematopoietic stem cell therapy(HSCT) showed clinical benefit but suggested further exploration must be done. [18] Findings using HSCT was beneficial in recessive disorders and saw that it may similarly enhance CSF1R signaling after partial loss seen in LENAS. [18] In the subjects who had LENAS were introduced to HSCT and the finding of further progressed cells was minimal 15 years after the therapy was finished. [18] The most important finding in the subject was that they retained a high level of communication and survived beyond 15 years after onset of symptoms. [18] This is very rare for LENAS as it has been reported to be averaged at 6.8 years for surviving after the onset. This finding provides hope for future research direction and suggests that there may be great benefit to slow the progression of LENAS using HSCT.

See also

Related Research Articles

Hereditary spastic paraplegia (HSP) is a group of inherited diseases whose main feature is a progressive gait disorder. The disease presents with progressive stiffness (spasticity) and contraction in the lower limbs. HSP is also known as hereditary spastic paraparesis, familial spastic paraplegia, French settlement disease, Strumpell disease, or Strumpell-Lorrain disease. The symptoms are a result of dysfunction of long axons in the spinal cord. The affected cells are the primary motor neurons; therefore, the disease is an upper motor neuron disease. HSP is not a form of cerebral palsy even though it physically may appear and behave much the same as spastic diplegia. The origin of HSP is different from cerebral palsy. Despite this, some of the same anti-spasticity medications used in spastic cerebral palsy are sometimes used to treat HSP symptoms.

<span class="mw-page-title-main">Lysosomal storage disease</span> Medical condition

Lysosomal storage diseases are a group of over 70 rare inherited metabolic disorders that result from defects in lysosomal function. Lysosomes are sacs of enzymes within cells that digest large molecules and pass the fragments on to other parts of the cell for recycling. This process requires several critical enzymes. If one of these enzymes is defective due to a mutation, the large molecules accumulate within the cell, eventually killing it.

<span class="mw-page-title-main">Demyelinating disease</span> Any neurological disease in which the myelin sheath of neurons is damaged

A demyelinating disease refers to any disease affecting the nervous system where the myelin sheath surrounding neurons is damaged. This damage disrupts the transmission of signals through the affected nerves, resulting in a decrease in their conduction ability. Consequently, this reduction in conduction can lead to deficiencies in sensation, movement, cognition, or other functions depending on the nerves affected.

<span class="mw-page-title-main">Alexander disease</span> Rare genetic disorder of the white matter of the brain

Alexander disease is a very rare autosomal dominant leukodystrophy, which are neurological conditions caused by anomalies in the myelin which protects nerve fibers in the brain. The most common type is the infantile form that usually begins during the first two years of life. Symptoms include mental and physical developmental delays, followed by the loss of developmental milestones, an abnormal increase in head size and seizures. The juvenile form of Alexander disease has an onset between the ages of 2 and 13 years. These children may have excessive vomiting, difficulty swallowing and speaking, poor coordination, and loss of motor control. Adult-onset forms of Alexander disease are less common. The symptoms sometimes mimic those of Parkinson's disease or multiple sclerosis, or may present primarily as a psychiatric disorder.

<span class="mw-page-title-main">CADASIL</span> Medical condition

CADASIL or CADASIL syndrome, involving cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, is the most common form of hereditary stroke disorder, and is thought to be caused by mutations of the Notch 3 gene on chromosome 19. The disease belongs to a family of disorders called the leukodystrophies. The most common clinical manifestations are migraine headaches and transient ischemic attacks or strokes, which usually occur between 40 and 50 years of age, although MRI is able to detect signs of the disease years prior to clinical manifestation of disease.

<span class="mw-page-title-main">Krabbe disease</span> Medical condition

Krabbe disease (KD) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessive pattern. The disease is named after the Danish neurologist Knud Krabbe (1885–1961).

<span class="mw-page-title-main">Leukodystrophy</span> Group of disorders characterised by degeneration of white matter in the brain

Leukodystrophies are a group of, usually, inherited disorders, characterized by degeneration of the white matter in the brain. The word leukodystrophy comes from the Greek roots leuko, "white", dys, "abnormal" and troph, "growth". The leukodystrophies are caused by imperfect growth or development of the glial cells which produce the myelin sheath, the fatty insulating covering around nerve fibers. Leukodystrophies may be classified as hypomyelinating or demyelinating diseases, respectively, depending on whether the damage is present before birth or occurs after. Other demyelinating diseases are usually not congenital and have a toxic or autoimmune cause.

Leukoencephalopathy is a term that describes all of the brain white matter diseases, whether their molecular cause is known or unknown. It can refer specifically to any of these diseases:

<span class="mw-page-title-main">Mitochondrial neurogastrointestinal encephalopathy syndrome</span> Medical condition

Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE) is a rare autosomal recessive mitochondrial disease. It has been previously referred to as polyneuropathy, ophthalmoplegia, leukoencephalopathy, and intestinal pseudoobstruction. The disease presents in childhood, but often goes unnoticed for decades. Unlike typical mitochondrial diseases caused by mitochondrial DNA (mtDNA) mutations, MNGIE is caused by mutations in the TYMP gene, which encodes the enzyme thymidine phosphorylase. Mutations in this gene result in impaired mitochondrial function, leading to intestinal symptoms as well as neuro-ophthalmologic abnormalities. A secondary form of MNGIE, called MNGIE without leukoencephalopathy, can be caused by mutations in the POLG gene.

<span class="mw-page-title-main">Leukoencephalopathy with vanishing white matter</span> Neurological disease

Leukoencephalopathy with vanishing white matter is an autosomal recessive neurological disease. The cause of the disease are mutations in any of the 5 genes encoding subunits of the translation initiation factor eIF2B: EIF2B1, EIF2B2, EIF2B3, EIF2B4, or EIF2B5. The disease belongs to a family of conditions called the Leukodystrophies.

<span class="mw-page-title-main">Infantile neuroaxonal dystrophy</span> Medical condition

Infantile neuroaxonal dystrophy (INAD) is a rare pervasive developmental disorder that primarily affects the nervous system. Individuals with infantile neuroaxonal dystrophy typically do not have any symptoms at birth, but between the ages of about 6 and 18 months they begin to experience delays in acquiring new motor and intellectual skills, such as crawling or beginning to speak. Eventually they lose previously acquired skills.

<span class="mw-page-title-main">Colony stimulating factor 1 receptor</span> Protein found in humans

Colony stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), and CD115, is a cell-surface protein encoded by the human CSF1R gene. CSF1R is a receptor that can be activated by two ligands: colony stimulating factor 1 (CSF-1) and interleukin-34 (IL-34). CSF1R is highly expressed in myeloid cells, and CSF1R signaling is necessary for the survival, proliferation, and differentiation of many myeloid cell types in vivo and in vitro. CSF1R signaling is involved in many diseases and is targeted in therapies for cancer, neurodegeneration, and inflammatory bone diseases.

Megalencephalic leukoencephalopathy with subcortical cysts is a form of hereditary CNS demyelinating disease. It belongs to a group of disorders called leukodystrophies. It is characterized by early-onset enlargement of the head (macrocephaly) as well as delayed-onset neurological deterioration to include spasticity, epilepsy, and lack of muscular coordination. MLC does not appear to be a disease that is fatal at birth or early in life despite its symptoms, although the number of patients throughout history known to have the disease is fairly limited.

Neurovirology is an interdisciplinary field which represents a melding of clinical neuroscience, virology, immunology, and molecular biology. The main focus of the field is to study viruses capable of infecting the nervous system. In addition to this, the field studies the use of viruses to trace neuroanatomical pathways, for gene therapy, and to eliminate detrimental populations of neural cells.

Neurodegeneration with brain iron accumulation is a heterogenous group of inherited neurodegenerative diseases, still under research, in which iron accumulates in the basal ganglia, either resulting in progressive dystonia, parkinsonism, spasticity, optic atrophy, retinal degeneration, neuropsychiatric, or diverse neurologic abnormalities. Some of the NBIA disorders have also been associated with several genes in synapse and lipid metabolism related pathways. NBIA is not one disease but an entire group of disorders, characterized by an accumulation of brain iron, sometimes in the presence of axonal spheroids in the central nervous system.

<span class="mw-page-title-main">Hereditary diffuse leukoencephalopathy with spheroids</span> Medical condition

Hereditary diffuse leukoencephalopathy with spheroids (HDLS) is a rare adult onset autosomal dominant disorder characterized by cerebral white matter degeneration with demyelination and axonal spheroids leading to progressive cognitive and motor dysfunction. Spheroids are axonal swellings with discontinuous or absence of myelin sheaths. It is believed that the disease arises from primary microglial dysfunction that leads to secondary disruption of axonal integrity, neuroaxonal damage, and focal axonal spheroids leading to demyelination. Spheroids in HDLS resemble to some extent those produced by shear stress in a closed head injury with damage to axons, causing them to swell due to blockage of axoplasmic transport. In addition to trauma, axonal spheroids can be found in aged brain, stroke, and in other degenerative diseases. In HDLS, it is uncertain whether demyelination occurs prior to the axonal spheroids or what triggers neurodegeneration after apparently normal brain and white matter development, although genetic deficits suggest that demyelination and axonal pathology may be secondary to microglial dysfunction. The clinical syndrome in patients with HDLS is not specific and it can be mistaken for Alzheimer's disease, frontotemporal dementia, atypical Parkinsonism, multiple sclerosis, or corticobasal degeneration.

<span class="mw-page-title-main">Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations</span> Medical condition

Retinal vasculopathy with cerebral leukocencephalopathyand systemic manifestations is an inherited condition resulting from a frameshift mutation in the C-terminal region of the TREX1 gene. This disease affects small blood vessels, leading to damage of multiple organs including but not limited to the retina and the white matter of the central nervous system. Patients with RVCL develop vision loss, brain lesions, strokes, brain atrophy, and dementia. Patients with RVCL also exhibit other organ involvement, including kidney, liver, gastrointestinal tract, thyroid, and bone disease. Symptoms of RVCL commonly begin between ages 35 and 55, although sometimes disease onset occurs earlier or later. The overall prognosis is poor, and death can sometimes occur within 5 or 10 years of the first symptoms appearing, although some patients live more than 20 years after initial symptoms. Clinical trials are underway, as are efforts to develop personalized medicines for patients with RVCL.

<span class="mw-page-title-main">Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy</span> Medical condition

Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is disease of the arteries in the brain, which causes tissue loss in the subcortical region of the brain and the destruction of myelin in the CNS. CARASIL is characterized by symptoms such as gait disturbances, hair loss, low back pain, dementia, and stroke. CARASIL is a rare disease, having only been diagnosed in about 50 patients, of which ten have been genetically confirmed. Most cases have been reported in Japan, but Chinese and caucasian individuals have also been diagnosed with the disease. CARASIL is inherited in an autosomal recessive pattern. There is currently no cure for CARASIL. Other names for CARASIL include familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension, Nemoto disease and Maeda syndrome.

Nasu–Hakola disease also known as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy is a rare disease characterised by early-onset dementia and multifocal bone cysts. It is caused by autosomal recessive loss of function mutations in either the TREM2 or TYROBP gene that are found most frequently in the Finnish and Japanese populations.

<span class="mw-page-title-main">Autosomal dominant leukodystrophy with autonomic disease</span> Medical condition

Autosomal dominant leukodystrophy with autonomic disease is a rare neurological condition of genetic origin which is characterized by gradual demyelination of the central nervous system which results in various impairments, including ataxia, mild cognitive disability and autonomic dysfunction. It is part of a group of disorders called "leukodystrophies".

References

  1. Adams, Scott J.; Kirk, Andrew; Auer, Roland N. (2018). "Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): Integrating the literature on hereditary diffuse leukoencephalopathy with spheroids (HDLS) and pigmentary orthochromatic leukodystrophy (POLD)". Journal of Clinical Neuroscience. 48: 42–49. doi:10.1016/j.jocn.2017.10.060. PMID   29122458.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 "Hereditary diffuse leukoencephalopathy with spheroids | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 2020-11-10.
  3. 1 2 3 4 5 6 7 8 "Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: MedlinePlus Genetics". medlineplus.gov. Retrieved 2020-11-10.
  4. Keegan BM, Giannini C, Parisi JE, Lucchinetti CF, Boeve BF, Josephs KA (March 2008). "Sporadic adult-onset leukoencephalopathy with neuroaxonal spheroids mimicking cerebral MS". Neurology. 70 (13 Pt 2): 1128–33. doi:10.1212/01.wnl.0000304045.99153.8f. PMID   18287567. S2CID   21341310.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Hereditary Diffuse Leukoencephalopathy with Spheroids (HDLS)". United Leukodystrophy Foundation. Retrieved 2020-11-10.
  6. 1 2 3 Lynch, David S.; Jaunmuktane, Zane; Sheerin, Una-Marie; Phadke, Rahul; Brandner, Sebastian; Milonas, Ionnis; Dean, Andrew; Bajaj, Nin; McNicholas, Nuala; Costello, Daniel; Cronin, Simon (2016-05-01). "Hereditary leukoencephalopathy with axonal spheroids: a spectrum of phenotypes from CNS vasculitis to parkinsonism in an adult onset leukodystrophy series". Journal of Neurology, Neurosurgery & Psychiatry. 87 (5): 512–519. doi: 10.1136/jnnp-2015-310788 . ISSN   0022-3050. PMC   4853550 . PMID   25935893.
  7. 1 2 3 4 "CSF1R gene: MedlinePlus Genetics". medlineplus.gov. Retrieved 2020-11-10.
  8. 1 2 Gaillard, Frank. "Subcortical U-fibers | Radiology Reference Article | Radiopaedia.org". Radiopaedia. Retrieved 2020-11-10.
  9. Ali, Zarina S.; Van Der Voorn, J. Patrick; Powers, James M. (July 2007). "A comparative morphologic analysis of adult onset leukodystrophy with neuroaxonal spheroids and pigmented glia--a role for oxidative damage". Journal of Neuropathology and Experimental Neurology. 66 (7): 660–672. doi: 10.1097/nen.0b013e3180986247 . ISSN   0022-3069. PMID   17620991.
  10. 1 2 3 4 5 6 Wider, C; Van Gerpen, J A.; DeArmond, S; Shuster, E A.; Dickson, D W.; Wszolek, Z K. (2009-06-02). "Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD)". Neurology. 72 (22): 1953–1959. doi:10.1212/WNL.0b013e3181a826c0. ISSN   0028-3878. PMC   2843560 . PMID   19487654.
  11. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Konno, T.; Yoshida, K.; Mizuta, I.; Mizuno, T.; Kawarai, T.; Tada, M.; Nozaki, H.; Ikeda, S.-I.; Onodera, O.; Wszolek, Z. K.; Ikeuchi, T. (January 2018). "Diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia due to CSF1R mutation". European Journal of Neurology. 25 (1): 142–147. doi:10.1111/ene.13464. PMC   5741468 . PMID   28921817.
  12. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Sundal, Christina; Wszolek, Zbigniew K. (1993), Adam, Margaret P.; Ardinger, Holly H.; Pagon, Roberta A.; Wallace, Stephanie E. (eds.), "CSF1R-Related Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia", GeneReviews®, Seattle (WA): University of Washington, Seattle, PMID   22934315 , retrieved 2020-11-11
  13. Van Gerpen, J. A.; Wider, C.; Broderick, D. F.; Dickson, D. W.; Brown, L. A.; Wszolek, Z. K. (2008-09-15). "Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids". Neurology. 71 (12): 925–929. doi:10.1212/01.wnl.0000325916.30701.21. ISSN   0028-3878. PMC   2843529 . PMID   18794495.
  14. Sundal, C.; Van Gerpen, J. A.; Nicholson, A. M.; Wider, C.; Shuster, E. A.; Aasly, J.; Spina, S.; Ghetti, B.; Roeber, S.; Garbern, J.; Borjesson-Hanson, A. (2012-08-07). "MRI characteristics and scoring in HDLS due to CSF1R gene mutations". Neurology. 79 (6): 566–574. doi:10.1212/wnl.0b013e318263575a. ISSN   0028-3878. PMC   3413763 . PMID   22843259.
  15. Konno, T.; Yoshida, K.; Mizuno, T.; Kawarai, T.; Tada, M.; Nozaki, H.; Ikeda, S.-I.; Nishizawa, M.; Onodera, O.; Wszolek, Z. K.; Ikeuchi, T. (2017). "Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation". European Journal of Neurology. 24 (1): 37–45. doi:10.1111/ene.13125. ISSN   1468-1331. PMC   5215554 . PMID   27680516.
  16. Wong, Janice C.; Chow, Tiffany W.; Hazrati, Lili-Naz (2011). "Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia Can Present as Frontotemporal Dementia Syndrome". Dementia and Geriatric Cognitive Disorders. 32 (2): 150–158. doi: 10.1159/000331422 . ISSN   1420-8008. PMID   21986056.
  17. 1 2 3 4 5 "UpToDate". www.uptodate.com. Retrieved 2020-11-11.
  18. 1 2 3 4 Eichler, Florian S.; Li, Jiankang; Guo, Yiran; Caruso, Paul A.; Bjonnes, Andrew C.; Pan, Jessica; Booker, Jessica K.; Lane, Jacqueline M.; Tare, Archana; Vlasac, Irma; Hakonarson, Hakon (June 2016). "CSF1R mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroids". Brain. 139 (6): 1666–1672. doi:10.1093/brain/aww066. ISSN   0006-8950. PMC   4892751 . PMID   27190017.